New drug shows promise for tough lymphomas in early trial

NCT ID NCT06485219

Ongoing Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a new drug called purinostat mesylate in 50 people with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. The drug is given by IV four times per 21-day cycle for up to 96 weeks. The main goal is to see if it can shrink tumors (objective remission rate), while also checking safety and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: purinostat mesylate
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat T-cell lymphomas, potentially shrinking tumors and controlling the disease.
What could go wrong: This is an early Phase 2 trial with only 50 participants, so results may not apply to everyone. The drug may cause side effects or fail to work in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA (CTCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T CELL LYMPHOMA (CTCL) RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL)

Contacts and locations

Locations

Ruijin Hospital, Shanghai Jiaotong University School Of Medicine

Shanghai, Shanghai Municipality, 200000, China
West China Hospital Sichuan University

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.